Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 244 posts found.

gilead-sciences

Gilead makes $567m strategic acquisition for next-gen CAR-T

December 8, 2017
Medical Communications, Sales and Marketing CAR-T, Cell Design Labs, Gilead, Kite, biotech, drugs, pharma, pharmaceutical

It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly …

News
gilead-sciences

Gilead launches hep C drug Sovaldi in China at one-fifth of US price

November 29, 2017
Research and Development, Sales and Marketing China, Gilead, hepatitis C, pharma, sovaldi

Gilead has officially launched its hepatitis C drug Sovaldi (sofosbuvir) in the Chinese market, but with one major caveat: it …

News
640px-hiv-budding-color

Learning lessons from HIV to change the treatment access landscape

November 23, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, HIV, pharma

Greg Alton, Executive Vice President of Corporate and Medical Affairs at Gilead, reveals how the rapid development and distribution of …

Feature
gsk_boronia_australia

FDA approves first-ever two-drug HIV regimen, GSK’s Juluca

November 22, 2017
Research and Development, Sales and Marketing AIDS, FDA, GSK, Gilead, GlaxoSmithKilne, HIV, Juluca, ViiV Healthcare, pharma

GlaxoSmithKline has announced that the FDA has awarded US marketing authorisation to the first two-drug regimen in the treatment of …

News
novartis_hq_day

Novartis aims for CAR-T double-approval in Europe

November 6, 2017
Sales and Marketing CAR-T, Gilead, Juno, Novartis, biotech, drugs, pharma, pharmaceutical

Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma …

News

Novartis reveals the data behind its showdown with Gilead

November 1, 2017
Research and Development CAR-T, Gilead, Kymriah, Novartis, biotech, drugs, pharma, pharmaceutical

Only yesterday it was revealed that Novartis had applied to the FDA in the same indication that Gilead’s treatment is …

News
_97604447_kymriah-product-shot-8

CAR-T is bringing true precision to the fight against cancer

November 1, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Gilead, Kymriah, Novartis, Yescarta

Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …

Feature
alessandro-riva

Gilead promotes Alessandro Riva to Senior VP, Hematology and Oncology Therapeutic Area Head

October 24, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, appointment

Gilead had revealed that it has promoted Dr Alessandro Riva, its Senior Vice President, Hematology and Oncology Therapeutic Area Head, …

Appointment
gilead-sciences

Gilead gets FDA nod for revolutionary blood cancer treatment

October 19, 2017
Sales and Marketing CAR-T, Gilead, Yescarta, biotech, drugs, pharma, pharmaceutical

Only weeks after Gilead announced the completion of Kite, it got the news it was hoping for with the FDA’s …

News
gilead-sciences

Gilead completes £11.9 billion Kite Pharma acquisition

October 5, 2017
Sales and Marketing CAR T, CAR-T, Gilead, Kite, acquisition, pharma, pharmaceuticals

Gilead has announced that it has completed its acquisition of Kite Pharma after the deal was announced on 28 August …

News
gilead_senior_management

Gilead’s COO retires, shares take a dive

September 29, 2017
Medical Communications Gilead, Kevin Young, biotech, drugs, pharma, pharmaceutical

Gilead has announced that Kevin Young, its Chief Operating Officer, is set to retire from the company in early 2018. …

News

Anti-HIV drug PrEP proves safety in gay and bisexual adolescents

September 6, 2017
Research and Development Gilead, HIV, Pharamceuticals, PrEP, Truvada, health, medicine, pharma

A new study has found that pre-exposure prophylaxis (PrEP) drugs such as Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate), which pre-emptively protects …

News
gilead-sciences

Gilead captures Kite in $11.9bn deal

August 29, 2017
Manufacturing and Production, Sales and Marketing Gilead, biotech, drugs, kite pharma, pharma, pharmaceutical

Gilead had long been expected to make a serious acquisition to boost flagging growth and it finally made a move …

News
gilead-sciences

Gilead set to open $250m, 23-acre campus

August 15, 2017
Manufacturing and Production Gilead, biotech, drugs, pharma, pharmaceutical

Gilead is set for the grand unveiling of its new facility in La Verne, Southern California, after several years of …

News
world_hep_day

Nine in 10 people unaware they have hepatitis

July 28, 2017
Medical Communications, Research and Development Gilead, biotech, drugs, hepatitis, hepatitis C, pharma, pharmaceutical

The WHO has released a report on the state of hepatitis prevention and treatment to mark World Hepatitis Day, with …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025